Background: The association between alcohol and caffeine intakes and risk of multiple sclerosis (MS) is unclear; no prospective studies have examined this relationship. Objective: We examined intakes of alcohol and caffeine in relation to risk of multiple sclerosis. Methods: Intakes of alcohol and caffeine were examined in relation to the risk of MS in two large cohorts of women, the Nurses' Health Study (NHS; 92,275 women followed from 1980 to 2004) and Nurses' Health Study II (NHS II; 95,051 women followed from 1991 to 2005). Their diet was assessed at baseline and every four years thereafter. During the follow-up, 282 cases of MS were confirmed with onset of symptoms after baseline. Twenty-four cases were missing information on alcohol intake, leaving a total of 258 cases for the alcohol analyses. Results: Neither total alcohol consumption, nor consumption of beer, wine, or liquor was related to MS risk. The multivariable-adjusted pooled relative risk (RR) found by comparing categories of alcohol intake to 0 gm/day was 1.07 (95% CI: 0.32-1.99) for 0.1-4.9 gm/day, 1.01 (0.32-1.99) for 5.0-14.9 gm/day, 1.21 (0.69-2.15) for 15.0-29.9 gm/day, and 0.80 (0.32-1.99) for 30+ gm/day; (p for trend=0.89). Caffeine intake was also not significantly associated with MS risk. The multivariable adjusted pooled RR comparing highest to lowest quintile of caffeine intake was 1.14; 95% CI: 0.79-1.66; p for trend=0.71. Consideration of caffeinated and decaffeinated coffee separately also yielded null results. Conclusion: These results do not support an association between alcohol and caffeine intakes and MS risk.
Introduction
Alcohol and caffeine are widely consumed substances with prominent effects on the central nervous system. 1 Although numerous longitudinal investigations have been conducted to examine the effects of habitual alcohol and caffeine consumption on several neurological diseases including stroke, 2, 3 Alzheimer's disease, 4, 5 and Parkinson's disease, 6, 7 there are no prospective studies addressing whether alcohol or caffeine consumption affect the risk of developing multiple sclerosis (MS). The relationship between alcohol or caffeine consumption and MS risk has only been examined in two case-control studies that generated inconsistent results. 8, 9 In animal experiments, ethanol seems to reduce a subset of CD 8+ T cells that is important for suppressing autoimmune activity, and could thus increase MS risk. 10, 11 However, the risk of other autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis, has been found to be lower in alcohol drinkers as compared to non-drinkers. 12, 13 In animal models of MS, chronic caffeine consumption was found to have a neuroprotective effect, potentially through an adenosine A1 receptor-mediated shift from Th1 to Th2 cell function. 14 However, there is little evidence for an association between caffeine intake and risk of rheumatoid arthritis, a condition that, like MS, is considered to be a cell-mediated autoimmune disease. 15, 16 Here we report the results of the first prospective study assessing the relationship between alcohol and caffeine consumption and risk of MS.
Methods

Standard protocol approval and study population
This study was approved by the institutional review board of Brigham and Women's Hospital.
The study population was drawn from the Nurses' Health Study (NHS) and Nurses' Health Study II (NHS II) comprising female registered nurses living in the United States. The NHS started in 1976 with 121,700 nurses aged 30 to 55 years; and the NHS II started in 1989 with 116,671 nurses aged 25 to 42 years. The first dietary assessment was conducted in the NHS in 1980, and in 1991 in NHS II, which was considered the beginning of follow-up for each cohort. Women were excluded from the analysis if they had implausible caloric intakes (<500 or >3,500 kcal/day in NHS, <800 or >4,200 kcal/day in NHS II) or MS symptoms that started before baseline. After these exclusions, there were 92,275 women in NHS and 95,051 women in NHS II available for the analysis.
Ascertainment of MS cases
Newly diagnosed cases of MS were identified by self report on biennial questionnaires and confirmed by asking the treating neurologist to complete a questionnaire on the certainty of diagnosis (definite, probable, possible, not MS), and clinical history (including date of diagnosis and date of first symptom of MS). In cases where a neurologist did not respond, we mailed a questionnaire to the patient's internist. The treating physician was a neurologist in 90% of women with MS and the diagnosis was supported by positive MRI (magnetic resonance imaging) findings in 76% (NHS) and 89% (NHS II) of the cases; no MRI results were available for the remaining confirmed cases. In this investigation we confirmed cases as those with definite or probable MS according to their neurologist or physician; the validity of this approach has been previously documented. 17 In these analyses, we considered 93 cases of MS (64 definite and 29 probable) in the NHS and 189 cases (136 definite and 53 probable) in the NHS II with onset of symptoms after baseline, for a total of 282 MS cases. Twenty-four cases were missing information on alcohol intake, leaving a total of 258 cases for the alcohol analyses.
Assessment of alcohol and caffeine intake
Comprehensive semi-quantitative food frequency questionnaires were completed by participants in the NHS in 1980, 1984, 1986, 1990, 1994, 1998, and 2002 and by those in NHS II in 1991 , 1995 , and 2003 . The NHS baseline questionnaire contained 61 food items; however, subsequent questionnaires were expanded to approximately 130 items. The validity and reproducibility of these food frequency questionnaires (FFQ) has been previously reported. 18, 19 The beverages that contributed to alcohol intake were beer, wine, and liquor. In a validation study, there were high correlations between intakes reported on the FFQ and those estimated from the four one-week diet records (correlation coefficient for beer: 0.94, wine: 0.90, liquor: 0.84). Similarly, those beverages contributing to caffeine intake also had high correlations (correlation coefficient for coffee: 0.78, tea: 0.93, cola: 0.84). 18 
Statistical analyses
Participants contributed person time to the follow up period from the date of return of their first food frequency questionnaire (1980 in NHS and 1991 in NHS II) to the date of onset of the first symptoms of MS, death from any cause, or end of follow-up (31 May 2004 for NHS and 31 May 2005 for NHS II). The median time from recruitment in the cohort to MS diagnosis was 7.3 years for NHS and 5.7 years for NHS II. Separate analyses were conducted for each cohort and the results were pooled. For main analyses, pre-determined cut off points of alcohol intake were used to categorize subjects (0, 0.1-4.9, 5.0-14.9, 15.0-29.9, 30+ gm/day). Fifteen gm of alcohol is approximately one drink (12 oz beer, 4-5 oz glass of wine, one shot of 80 proof liquor). Separate effects of beer, wine, and liquor were considered as continuous variables and each reported as relative risk (RR) for an increment of 10 gm of alcohol per day. The main analyses for caffeine were conducted by categorizing women into quintiles of intake. The effects of caffeinated and decaffeinated coffee were also considered in the following categories: never, <1 cup/day, 1-3 cups/day, and ≥3 cups/day. To account for changes in consumption over time, and to reduce random variation, we used as primary exposures the cumulative averages of alcohol, caffeine or coffee intake calculated from all available dietary questionnaires up to the start of each two-year follow up period. 20 Cox proportional hazards models were used to estimate RR adjusted for age (five-year age groups) and other potential risk factors for MS, including total intake of vitamin D from diet and supplements (IU /day in quintiles), latitude at age 15 years (northern, middle, southern states), pack years of smoking (0, <10 pks/yr, 10-24 pks/ yr, 25+ pks/yr), and ethnicity (southern European, Scandinavian, other Caucasian, and non-white). Between body mass index during adolescence and alcohol (NHS r2=0.04, NHS II correlation coefficient r2=0.06) and caffeine intakes correlations were low (NHS r2=0.09, NHS II correlation coefficient r2=0.08) and therefore not considered in the multivariable adjusted models. Tests for trend were conducted by using the median values of each category of intake as a continuous variable. Pooled RR estimates were calculated by combining data from both cohorts using the inverse of the variance of the relative risk as the weight, and the heterogeneity of the RR estimates from the two cohorts was tested using a Q test, where the squared difference between log RR was divided by the sum of the variances of each log RR. 21 All p values were two-sided.
Results
Women in the two highest categories of alcohol intake, after adjusting for age, consumed more total calories, had more pack years of smoking, and had a lower vitamin D intake than non-drinkers ( Table 1) . The test for heterogeneity between NHS and NHS II for alcohol was not significant (p=0.78), therefore we pooled the results. Intake of alcohol was not associated with the risk of MS ( Table 2 ). The multivariable-adjusted pooled RRs comparing Lastly, no associations were found when beer, liquor, and wine were considered separately ( Table 3) .
Extent of caffeine intake, similarly to alcohol consumption, was associated with smoking and with lower vitamin D intake. (Table 4 ). The test for heterogeneity of the RR estimates relating caffeine consumption to MS risk was not significant (p=0.20), so the results for NHS and NHS II were pooled. No association was found between caffeine intake and the risk of MS. The multivariable-adjusted pooled RR comparing highest (Q5) to lowest (Q1) quintile of caffeine intake was 1.14 (95% CI: 0.79-1.66; p for trend=0.71) ( Table 5 ). Similar null results were found for caffeinated and decaffeinated coffee ( Table 6 ).
Discussion
In this large prospective study of women, we found no association between intake of alcohol or caffeine and risk of MS. Specific sources of alcohol and caffeine were also found to have no association with MS risk. The strengths of our study include its prospective design, a high follow up response rate, repeated and validated assessments of diet, and detailed data on many potential confounders. These factors reduce the chance that bias influenced our results. Some misclassification of exposure is inevitable because average alcohol and caffeine intakes were assessed by questionnaires. However, as demonstrated in validation studies among participants in these cohorts, both alcohol and caffeine consumption are reported more accurately than most other dietary items, with correlations between the average intakes reported in the questionnaires and those recorded during four weeks of diet records ranging between 0.78-0.93. 18 Alcohol intake self-report was further validated by comparison with plasma levels of highdensity lipoprotein. 22 An earlier review article of studies of MS cases with, and without, control groups reported no association between alcohol consumption and risk of MS but did suggest that there may be a link with alcohol abuse (Hawkes 2005 ). 23 Another population-based case control study also found no difference between alcohol consumption of MS patients and the general population (Nortvedt 2005) . 24 However, significant associations between hard liquor and wine and coffee and tea consumption were reported from two other studies based in Italy and Belgrade. 25, 26 These studies, which were either case control in design or had no controls, are prone to both recall and selection bias and provide only weak evidence of an association. There may also be confounded by vitamin D intake, which we found to be smaller in the highest categories of alcohol and caffeine intake in our study. MS risk has been documented to be lower in those with the highest intakes of supplemental vitamin D. 27 In conclusion, the results of this large longitudinal investigation among two well-established cohorts of white US women suggest that neither alcohol nor caffeine intake affect the risk of MS.
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